High materiality7/10
Evommune price target lowered to $26 from $55 at Morgan Stanley
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Morgan Stanley lowers EVMN price target to $26 from $55; current price $15.05.
- Target cut to $26; current price $15.05; upside remains above the current price.
Key facts
- 01
Target: $26
- 02
Posted price: $15.05
- 03
Analyst firm: Morgan Stanley
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.